Sachetta LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Sachetta LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 7.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,010 shares of the biopharmaceutical company’s stock after buying an additional 342 shares during the period. Sachetta LLC’s holdings in Pfizer were worth $140,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Dorsey & Whitney Trust CO LLC increased its holdings in Pfizer by 6.8% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 77,406 shares of the biopharmaceutical company’s stock valued at $2,166,000 after buying an additional 4,939 shares during the last quarter. LGT Fund Management Co Ltd. increased its stake in shares of Pfizer by 4,615.0% in the 2nd quarter. LGT Fund Management Co Ltd. now owns 400,772 shares of the biopharmaceutical company’s stock worth $11,214,000 after purchasing an additional 392,272 shares in the last quarter. LGT Group Foundation raised its holdings in Pfizer by 2.5% in the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after purchasing an additional 18,274 shares during the period. Longfellow Investment Management Co. LLC lifted its position in Pfizer by 9.5% during the second quarter. Longfellow Investment Management Co. LLC now owns 291,837 shares of the biopharmaceutical company’s stock valued at $8,166,000 after purchasing an additional 25,430 shares in the last quarter. Finally, Liberty Wealth Management LLC bought a new stake in Pfizer during the second quarter valued at about $700,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.1 %

Shares of PFE stock opened at $29.74 on Wednesday. The stock’s 50-day moving average price is $29.12 and its 200-day moving average price is $28.08. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.62. The stock has a market capitalization of $168.50 billion, a price-to-earnings ratio of -495.50, a price-to-earnings-growth ratio of 1.00 and a beta of 0.68. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the firm earned $0.67 EPS. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.65%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

Several research firms have recently commented on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.